TD Cowen analyst Josh Jennings has reiterated their bullish stance on CBLL stock, giving a Buy rating on April 11.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Josh Jennings has given his Buy rating due to a combination of factors that highlight Ceribell, Inc.’s promising commercial trajectory. The company’s technology is proving effective in both clinical and economic terms, which is enhancing its appeal to hospitals across the United States. This positive feedback from healthcare professionals strengthens the belief in Ceribell’s market potential.
Furthermore, Ceribell’s impressive revenue growth since its IPO in October 2024 underscores its capability to perform among the top-tier companies in the MedTech sector. With a strong revenue growth of 48% in the third quarter followed by 41% in the fourth quarter of 2024, the company is on a solid path. Management’s revenue guidance for 2025, coupled with strategic expansion plans, including increasing territory managers, suggests a sustainable growth outlook, reinforcing the Buy recommendation.